We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $542M
1-Year Est. Return 206.64%
This Fund
S&P 500
This Quarter Est. Return
+0.61%
1 Year Est. Return
+206.64%
3 Year Est. Return
+724.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$499M
AUM Growth
-$206M
Cap. Flow
-$143M
Cap. Flow %
-28.66%
Top 10 Hldgs %
71.5%
Holding
65
New
10
Increased
6
Reduced
11
Closed
15

Top Buys

Rank Stock Value
1
ALMS
Alumis Inc
ALMS
+$8.13M
2
MRK icon
Merck
MRK
+$5.39M
3
JNJ icon
Johnson & Johnson
JNJ
+$5.26M
4
TERN
Terns Pharmaceuticals
TERN
+$4.3M
5
BIIB icon
Biogen
BIIB
+$3.4M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$27.4M
2
UGL icon
ProShares Ultra Gold
UGL
+$24.5M
3
QURE icon
uniQure
QURE
+$24.5M
4
SLNO
Soleno Therapeutics
SLNO
+$18.2M
5
VKTX icon
Viking Therapeutics
VKTX
+$17.3M

Sector Composition

Rank Sector Weight
1 Healthcare 88.81%
2 Miscellaneous 11.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLYS icon
26
Mineralys Therapeutics
MLYS
$2.75B
$3.73M 0.75%
137,800
– –
ROIV icon
27
Roivant Sciences
ROIV
$30B
$3.6M 0.72%
129,800
– –
PALI icon
28
Palisade Bio
PALI
$383M
$3.49M 0.7%
1,992,367
– –
BIIB icon
29
Biogen
BIIB
$31.4B
$3.38M 0.68%
+18,437
New +$3.4M
PROK icon
30
ProKidney
PROK
$416M
$3.23M 0.65%
1,806,939
-31,472
-2% -$66.8K
ABBV icon
31
AbbVie
ABBV
$440B
$3.15M 0.63%
14,500
– –
UTHR icon
32
United Therapeutics
UTHR
$21.4B
$2.96M 0.59%
5,000
– –
DRUG
33
Bright Minds Biosciences
DRUG
$657M
$2.8M 0.56%
38,407
+5,000
+15% +$402K
PTGX icon
34
Protagonist Therapeutics
PTGX
$9.44B
$2.42M 0.48%
22,931
-20
-0.1% -$1.77K
SLNO
35
DELISTED
Soleno Therapeutics
SLNO
$2.29M 0.46%
68,490
-465,208
-87% -$18.2M
BTSG icon
36
BrightSpring Health Services
BTSG
$12.4B
$2.29M 0.46%
53,800
+12,200
+29% +$491K
TVTX icon
37
Travere Therapeutics
TVTX
$6.23B
$2.1M 0.42%
70,700
– –
EWTX icon
38
Edgewise Therapeutics
EWTX
$4.76B
$2.06M 0.41%
+65,500
New +$1.89M
CELC icon
39
Celcuity
CELC
$4.55B
$1.78M 0.36%
15,576
+2,676
+21% +$292K
BBIO icon
40
BridgeBio Pharma
BBIO
$14.6B
$1.51M 0.3%
20,400
– –
KNSA icon
41
Kiniksa Pharmaceuticals
KNSA
$6.01B
$1.41M 0.28%
29,200
– –
CYTK icon
42
Cytokinetics
CYTK
$10.5B
$1.07M 0.22%
+16,300
New +$1.04M
ELVN icon
43
Enliven Therapeutics
ELVN
$4.35B
$819K 0.16%
+20,900
New +$579K
PRAX icon
44
Praxis Precision Medicines
PRAX
$9.84B
$805K 0.16%
2,500
– –
TENX icon
45
Tenax Therapeutics
TENX
$74.1M
$673K 0.13%
42,080
– –
KOD icon
46
Kodiak Sciences
KOD
$2.2B
$649K 0.13%
17,019
– –
NUVL
47
DELISTED
Nuvalent
NUVL
$502K 0.1%
4,900
-3,200
-40% -$326K
APGE
48
DELISTED
Apogee Therapeutics
APGE
$495K 0.1%
+5,886
New +$427K
AVTX icon
49
Avalo Therapeutics
AVTX
$1.06B
$433K 0.09%
28,970
-12,600
-30% -$197K
PEPG icon
50
PepGen
PEPG
$222M
$363K 0.07%
205,324
– –
1
2
3

Similar funds

CA
CV Advisors Aventura, Florida $542M AUM 24.89% 1-Year Est. Return
WCM
Westerly Capital Management San Francisco, California $542M AUM 48.48% 1-Year Est. Return
LI
Louisbourg Investments Dieppe, New Brunswick, Canada $542M AUM 21.44% 1-Year Est. Return
CWWM
Clear Wave Wealth Management Red Bank, New Jersey $541M AUM
FVCM
F&V Capital Management Boca Raton, Florida $542M AUM 46.38% 1-Year Est. Return
LI
Lafayette Investments Ashton, Maryland $542M AUM 22.5% 1-Year Est. Return
CCT
Chemung Canal Trust Elmira, New York $541M AUM 32.42% 1-Year Est. Return
MFS
Madrona Financial Services Everett, Washington $543M AUM 30.87% 1-Year Est. Return

Artia Global Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Artia Global Partners held 65 positions worth $499M, down 29% from $706M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Artia Global Partners withdrew a net $143M in Q1 2026, closing 15 positions and reducing 11 holdings. Its most notable exit was ProShares Ultra Gold, an estimated $24.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 85% a quarter earlier, followed by Miscellaneous.

Against the trend, Artia Global Partners opened a new position in Alumis Inc worth $7.16M.

  • Artia Global Partners's largest Q1 2026 buy was Alumis Inc: 325,046 shares worth $7.16M.
  • Artia Global Partners added most to Revolution Medicines in Q1 2026, an estimated $2.1M increase.
  • Artia Global Partners's biggest Q1 2026 reduction was argenx, cutting an estimated $27.4M.
  • Artia Global Partners fully exited ProShares Ultra Gold in Q1 2026, selling an estimated $24.5M.
  • Artia Global Partners's ten largest holdings make up 72% of its $499M portfolio in Q1 2026.
  • Artia Global Partners opened 10 new positions and closed 15 in Q1 2026.
  • Artia Global Partners's portfolio value fell 29% quarter-over-quarter to $499M.

Based on Artia Global Partners's 13F filing for Q1 2026, filed 15 May 2026.